H

Hugel Inc
KOSDAQ:145020

Watchlist Manager
Hugel Inc
KOSDAQ:145020
Watchlist
Price: 279 500 KRW -0.36%
Market Cap: 3.5T KRW
Have any thoughts about
Hugel Inc?
Write Note

Hugel Inc
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hugel Inc
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
H
Hugel Inc
KOSDAQ:145020
Total Assets
â‚©943B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Total Assets
â‚©19.9T
CAGR 3-Years
53%
CAGR 5-Years
39%
CAGR 10-Years
24%
SK Bioscience Co Ltd
KRX:302440
Total Assets
â‚©1.9T
CAGR 3-Years
49%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Total Assets
â‚©2.8T
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
8%
P
PharmaResearch Co Ltd
KOSDAQ:214450
Total Assets
â‚©640.8B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Total Assets
â‚©299.4B
CAGR 3-Years
6%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Hugel Inc
Glance View

Market Cap
3.5T KRW
Industry
Biotechnology

In the bustling landscape of the global biopharmaceutical market, Hugel Inc. stands out as a formidable player rooted in the dynamic world of aesthetics and medical treatments. Established in South Korea, Hugel Inc. embarked on its journey with a focus on producing botulinum toxin products, a niche that has rapidly expanded due to a surge in demand for non-surgical cosmetic procedures. The company navigated early challenges with innovative prowess, crafting a strong reputation for high-quality products that cater to a global clientele. The ethos of innovation and safety permeates its operations, enabling Hugel to diversify its portfolio and steadily gain traction in international markets, including significant footprints in Asia, Europe, and Latin America. Through a network of strategic partnerships and a robust distribution channel, Hugel not only pioneered advancements in cosmetic treatments but also cemented its status as a key contributor to the evolving aesthetics industry. The company's revenue model hinges upon the development, production, and distribution of its botulinum toxin and hyaluronic acid-based products. By focusing on research and development, Hugel enhances its capacity to innovate, delivering cutting-edge solutions that meet the rising demands of beauty-conscious consumers. Its business strategy also extends to therapeutics, exploring potential applications of its core products to address various medical conditions. Hugel's financial growth is propelled by the continuous expansion into new geographical territories and the gradual introduction of new, clinically-researched products. As the company continues to navigate the intricate regulatory landscapes of the pharmaceutical industry, it maintains an unwavering commitment to quality, ensuring that each product meets rigorous safety standards while catering to the evolving desires of its diverse customer base worldwide.

Intrinsic Value
251 724.56 KRW
Overvaluation 10%
Intrinsic Value
Price
H

See Also

What is Hugel Inc's Total Assets?
Total Assets
943B KRW

Based on the financial report for Sep 30, 2024, Hugel Inc's Total Assets amounts to 943B KRW.

What is Hugel Inc's Total Assets growth rate?
Total Assets CAGR 5Y
1%

Over the last year, the Total Assets growth was -5%. The average annual Total Assets growth rates for Hugel Inc have been -2% over the past three years , 1% over the past five years .

Back to Top